ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "84f8e418-4b97-46a5-8072-b75dd03eac9b"}, "_deposit": {"created_by": 21, "id": "291", "owners": [21], "pid": {"revision_id": 0, "type": "depid", "value": "291"}, "status": "published"}, "_oai": {"id": "oai:agi.repo.nii.ac.jp:00000291", "sets": ["44"]}, "author_link": ["334"], "item_10007_date_8": {"attribute_name": "報告年度", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2023-03", "subitem_date_issued_type": "Issued"}]}, "item_10007_description_13": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Access to drugs is crucial for achieving Sustainable Development Goal 3 of the United Nations, which aims to promote good health and well-being for all. Improving access to drugs requires addressing availability, affordability, and adoption. Availability refers to the physical presence of medicines in healthcare facilities or in the market, which is influenced by production capacity, quality control, regulatory approval processes, procurement and tendering processes. Affordability, on the other hand, refers to the ability of individuals and health systems to acquire and pay for drugs. High drug prices, intellectual property protection, market competition, government policies, and drug development expenses can create significant barriers to affordability. Finally, adoption is the utilization of drugs by healthcare providers and patients, which is influenced by clinical decision-making, prescribing practices, and patient preferences. Even if drugs are available and affordable, they may not be adopted if healthcare providers and patients do not perceive them as safe and effective.\nWhile addressing all three elements is important for improving access to drugs, it can be challenging and may require trade-offs between different interests, especially when resources and budgets are limited. For example, reducing drug prices to enhance affordability may lead to lower revenues for drug manufacturers, which could deter them from investing in research and development. This, in turn, could affect the availability of innovative medicines in the long run, particularly for neglected diseases or conditions that disproportionately affect marginalized populations.\nTo help policymakers anticipate the long-term implications of drug pricing and availability, rigorous economic evaluation of existing policies is crucial. However, the lack of data remains a significant obstacle to this evaluation, highlighting the need for further research in this area. This report provides a historical overview of the Chinese pharmaceutical market and the evolution of drug policies that have affected accessibility. It also provides a summary of recent initiatives to improve drug availability and their results based on existing evidence. The overview and additional preliminary descriptive analyses are part of the overall drug access research program, and they are expected to provide the basis for a quantitative evaluation of policy effects in future studies.", "subitem_description_type": "Abstract"}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2023-04-17"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "report2022-05.pdf", "filesize": [{"value": "514.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_11", "mimetype": "application/pdf", "size": 514000.0, "url": {"label": "report2022-05", "url": "https://agi.repo.nii.ac.jp/record/291/files/report2022-05.pdf"}, "version_id": "70bfb517-1623-4213-8b22-fe7e695f151a"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_researcher": {"attribute_name": "研究代表者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorAffiliations": [{"affiliationNameIdentifiers": [{"affiliationNameIdentifier": "", "affiliationNameIdentifierScheme": "ISNI", "affiliationNameIdentifierURI": "http://www.isni.org/isni/"}], "affiliationNames": [{"affiliationName": "", "affiliationNameLang": "ja"}]}], "creatorNames": [{"creatorName": "姚, 瑩", "creatorNameLang": "ja"}, {"creatorName": "Yao, Ying", "creatorNameLang": "en"}], "familyNames": [{"familyName": "姚", "familyNameLang": "ja"}, {"familyName": "Yao", "familyNameLang": "en"}], "givenNames": [{"givenName": "瑩", "givenNameLang": "ja"}, {"givenName": "Ying", "givenNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "334", "nameIdentifierScheme": "WEKO"}]}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "research report", "resourceuri": "http://purl.org/coar/resource_type/c_18ws"}]}, "item_title": "Exploring the State of Pharmaceutical Access in China", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Exploring the State of Pharmaceutical Access in China"}]}, "item_type_id": "10007", "owner": "21", "path": ["44"], "permalink_uri": "https://agi.repo.nii.ac.jp/records/291", "pubdate": {"attribute_name": "公開日", "attribute_value": "2023-04-17"}, "publish_date": "2023-04-17", "publish_status": "0", "recid": "291", "relation": {}, "relation_version_is_last": true, "title": ["Exploring the State of Pharmaceutical Access in China"], "weko_shared_id": -1}
  1. 調査報告書
  2. 2022年

Exploring the State of Pharmaceutical Access in China

https://agi.repo.nii.ac.jp/records/291
https://agi.repo.nii.ac.jp/records/291
edbe1f21-c9d6-40aa-af0f-ba0109a2ad05
名前 / ファイル ライセンス アクション
report2022-05.pdf report2022-05 (514.0 kB)
license.icon
Item type 報告書 / Research Paper(1)
公開日 2023-04-17
タイトル
タイトル Exploring the State of Pharmaceutical Access in China
言語
言語 jpn
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_18ws
資源タイプ research report
研究代表者 姚, 瑩

× 姚, 瑩

WEKO 334

ja 姚, 瑩
ISNI

en Yao, Ying

Search repository
報告年度
日付 2023-03
日付タイプ Issued
抄録
内容記述タイプ Abstract
内容記述 Access to drugs is crucial for achieving Sustainable Development Goal 3 of the United Nations, which aims to promote good health and well-being for all. Improving access to drugs requires addressing availability, affordability, and adoption. Availability refers to the physical presence of medicines in healthcare facilities or in the market, which is influenced by production capacity, quality control, regulatory approval processes, procurement and tendering processes. Affordability, on the other hand, refers to the ability of individuals and health systems to acquire and pay for drugs. High drug prices, intellectual property protection, market competition, government policies, and drug development expenses can create significant barriers to affordability. Finally, adoption is the utilization of drugs by healthcare providers and patients, which is influenced by clinical decision-making, prescribing practices, and patient preferences. Even if drugs are available and affordable, they may not be adopted if healthcare providers and patients do not perceive them as safe and effective.
While addressing all three elements is important for improving access to drugs, it can be challenging and may require trade-offs between different interests, especially when resources and budgets are limited. For example, reducing drug prices to enhance affordability may lead to lower revenues for drug manufacturers, which could deter them from investing in research and development. This, in turn, could affect the availability of innovative medicines in the long run, particularly for neglected diseases or conditions that disproportionately affect marginalized populations.
To help policymakers anticipate the long-term implications of drug pricing and availability, rigorous economic evaluation of existing policies is crucial. However, the lack of data remains a significant obstacle to this evaluation, highlighting the need for further research in this area. This report provides a historical overview of the Chinese pharmaceutical market and the evolution of drug policies that have affected accessibility. It also provides a summary of recent initiatives to improve drug availability and their results based on existing evidence. The overview and additional preliminary descriptive analyses are part of the overall drug access research program, and they are expected to provide the basis for a quantitative evaluation of policy effects in future studies.
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-20 15:58:55.988544
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3